CLL geassocieerde studies

Open studies

Naam	CELESTIAL-TNCLL study
Titel	A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia.
Status	Open
Reference	Clinicaltrials.gov: NCT06073821
Populatie	Treatment-naïve (TN) adults with confirmed diagnosis of CLL which requires treatment, 18 Years and older (Adult, Older Adult)
Deelnemers	Martini Ziekenhuis - Groningen - Schreurs Ikazia Ziekenhuis - Rotterdam - de Boer Hagaziekenhuis - Den Haag - Kersting Albert Schweitzer hospital - Dordrecht - Levin Meander MC - Amersfoort - Regelink Maasstad Ziekenhuis - Rotterdam - Sandberg Franciscus Gasthuis & Vlietland - Schiedam - Boiten Reinier de Graaf Gasthuis - Delft - Posthuma Noordwest Ziekenhuisgroep locatie Alkmaar - Alkmaar - Visser Elisabeth-TweeSteden Ziekenhuis (ETZ) - Tilburg - Droogendijk AmsterdamUMC - Amsterdam - Kater Flevoziekenhuis - Almere - Kater
Documenten	In- en exclusiecriteria

Naam	M18-803 T-PLL
Titel	A Prospective, Open-Label, Single-Arm, Phase 2, Multicenter Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Subjects with T-Cell Prolymphocytic Leukemia
Referentie	Clinicaltrials.gov: NCT03873493
Status	Open
Deelnemers	M. Bellido, Universitair Medisch Centrum, Groningen; m.bellido@umcg.nl L. Tick, Maxima Medisch Centrum, Eindhoven; l.Tick@mmc.nl
Documenten	In- en exclusiecriteria

Naam	ACE-CL-311
Titel	A Randomized, Multicenter, Open-Label, Phase 3 Study to Compare the Efficacy and Safety of Acalabrutinib (ACP-196) in Combination with Venetoclax with and without Obinutuzumab Compared to Investigator’s Choice of Chemoimmunotherapy in Subjects with Previously Untreated Chronic Lymphocytic Leukemia Without del(17p) or TP53 Mutation.
Referentie	Clinicaltrials.gov: NCT04008706
Status	Open
Deelnemers	AmsterdamUMC - location AMC – Arnon Kater Flevoziekenhuis – Koen de Heer
Documenten	Flow + Eligibility criteria

Naam	ACE-CL-312
Titel	A Phase 3b, Multicenter, Open-Label, Single-Arm Study of Acalabrutinib (ACP-196) in Subjects with Chronic Lymphocytic Leukemia
Referentie	Clinicaltrials.gov: NCT04008706
Status	Open only for patients with prior BTKi therapy (Cohort3) (Other cohorts: Treatment-naive patients and enrollment of patients with Relapsed/Refractory disease are complete)
Deelnemers	Open in: Universitair Medisch Centrum Utrecht (Utrecht) Rogier Mous (r.mous@umcutrecht.nl) Will also be opened in: Albert Schweitzer Ziekenhuis (Dordrecht), Mark-David Levin HagaZiekenhuis (Den Haag), Sabina Kersting Rijnstate Ziekenhuis (Arnhem) Ellen vd Spek Isala Klinieken (Zwolle), Ellen Dompeling
Documenten	Flow + Eligibility criteria

Up